BD Biosciences and Roche Collaborate on Study of Cell Signal Transduction through New Phosphorylation Site Antibody Targets

28-Feb-2007

BD Biosciences, a segment of BD (Becton, Dickinson and Company), and Roche announced a new collaboration to jointly identify and develop intracellular phosphorylation site antibodies that will improve their understanding of the pathways that carry information inside of cells and why these pathways sometimes malfunction to cause disease. These insights could ultimately lead to the discovery of new drugs and biological markers for life-threatening and debilitating conditions.

Under the terms of the agreement, Roche and BD will share information and resources to identify intracellular phosphorylation site target specificities of high interest in a number of disease areas. The two companies will also develop and validate antibodies for those targets using BD Phosflow(TM) technology and in other cell and tissue analysis applications. Roche will receive nonexclusive pre-launch access to all developmental BD Phosflow antibodies and a period of exclusive commercial access to those validated antibodies.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous